![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: DOLK |
Gene summary for DOLK |
![]() |
Gene information | Species | Human | Gene symbol | DOLK | Gene ID | 22845 |
Gene name | dolichol kinase | |
Gene Alias | CDG1M | |
Cytomap | 9q34.11 | |
Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | A0A0S2Z597 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
22845 | DOLK | C04 | Human | Oral cavity | OSCC | 2.29e-02 | 2.83e-01 | 0.2633 |
22845 | DOLK | C21 | Human | Oral cavity | OSCC | 3.00e-21 | 6.16e-01 | 0.2678 |
22845 | DOLK | C30 | Human | Oral cavity | OSCC | 4.77e-34 | 1.33e+00 | 0.3055 |
22845 | DOLK | C38 | Human | Oral cavity | OSCC | 6.85e-08 | 6.84e-01 | 0.172 |
22845 | DOLK | C43 | Human | Oral cavity | OSCC | 1.07e-05 | 1.19e-01 | 0.1704 |
22845 | DOLK | C46 | Human | Oral cavity | OSCC | 5.67e-05 | 2.23e-01 | 0.1673 |
22845 | DOLK | C57 | Human | Oral cavity | OSCC | 4.60e-02 | 1.56e-01 | 0.1679 |
22845 | DOLK | C06 | Human | Oral cavity | OSCC | 7.80e-05 | 6.57e-01 | 0.2699 |
22845 | DOLK | C08 | Human | Oral cavity | OSCC | 1.32e-08 | 1.98e-01 | 0.1919 |
22845 | DOLK | SYSMH1 | Human | Oral cavity | OSCC | 1.23e-07 | 1.94e-01 | 0.1127 |
22845 | DOLK | SYSMH2 | Human | Oral cavity | OSCC | 2.33e-06 | 1.68e-01 | 0.2326 |
22845 | DOLK | SYSMH3 | Human | Oral cavity | OSCC | 6.04e-11 | 2.42e-01 | 0.2442 |
22845 | DOLK | SYSMH6 | Human | Oral cavity | OSCC | 2.69e-06 | 8.30e-02 | 0.1275 |
22845 | DOLK | P1_cSCC | Human | Skin | cSCC | 1.56e-08 | 2.91e-01 | 0.0292 |
22845 | DOLK | P2_cSCC | Human | Skin | cSCC | 5.59e-06 | 2.36e-01 | -0.024 |
22845 | DOLK | P4_cSCC | Human | Skin | cSCC | 8.37e-04 | 1.72e-01 | -0.00290000000000005 |
22845 | DOLK | P10_cSCC | Human | Skin | cSCC | 2.95e-08 | 2.55e-01 | 0.1017 |
Page: 1 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00064875 | Oral cavity | OSCC | protein N-linked glycosylation | 44/7305 | 65/18723 | 2.63e-06 | 3.26e-05 | 44 |
GO:00086543 | Oral cavity | OSCC | phospholipid biosynthetic process | 130/7305 | 253/18723 | 3.96e-05 | 3.46e-04 | 130 |
GO:0006488 | Oral cavity | OSCC | dolichol-linked oligosaccharide biosynthetic process | 15/7305 | 18/18723 | 1.53e-04 | 1.07e-03 | 15 |
GO:00091001 | Oral cavity | OSCC | glycoprotein metabolic process | 185/7305 | 387/18723 | 2.37e-04 | 1.54e-03 | 185 |
GO:0006490 | Oral cavity | OSCC | oligosaccharide-lipid intermediate biosynthetic process | 15/7305 | 19/18723 | 4.64e-04 | 2.76e-03 | 15 |
GO:00091011 | Oral cavity | OSCC | glycoprotein biosynthetic process | 151/7305 | 317/18723 | 1.01e-03 | 5.26e-03 | 151 |
GO:00064864 | Oral cavity | OSCC | protein glycosylation | 111/7305 | 226/18723 | 1.22e-03 | 6.10e-03 | 111 |
GO:00434134 | Oral cavity | OSCC | macromolecule glycosylation | 111/7305 | 226/18723 | 1.22e-03 | 6.10e-03 | 111 |
GO:00700853 | Oral cavity | OSCC | glycosylation | 117/7305 | 240/18723 | 1.29e-03 | 6.42e-03 | 117 |
GO:00066445 | Oral cavity | OSCC | phospholipid metabolic process | 175/7305 | 383/18723 | 4.21e-03 | 1.71e-02 | 175 |
GO:00064877 | Skin | cSCC | protein N-linked glycosylation | 33/4864 | 65/18723 | 1.63e-05 | 1.99e-04 | 33 |
GO:00064883 | Skin | cSCC | dolichol-linked oligosaccharide biosynthetic process | 10/4864 | 18/18723 | 7.25e-03 | 3.44e-02 | 10 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa005105 | Oral cavity | OSCC | N-Glycan biosynthesis | 39/3704 | 53/8465 | 9.77e-06 | 4.36e-05 | 2.22e-05 | 39 |
hsa0051012 | Oral cavity | OSCC | N-Glycan biosynthesis | 39/3704 | 53/8465 | 9.77e-06 | 4.36e-05 | 2.22e-05 | 39 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
DOLK | SNV | Missense_Mutation | rs779503646 | c.839N>A | p.Arg280His | p.R280H | Q9UPQ8 | protein_coding | tolerated(0.25) | benign(0.001) | TCGA-DF-A2KU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
DOLK | SNV | Missense_Mutation | novel | c.720N>A | p.Phe240Leu | p.F240L | Q9UPQ8 | protein_coding | tolerated(0.72) | benign(0.003) | TCGA-EO-A22U-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
DOLK | SNV | Missense_Mutation | novel | c.1613N>T | p.Ala538Val | p.A538V | Q9UPQ8 | protein_coding | deleterious_low_confidence(0) | benign(0.009) | TCGA-EO-A3B0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
DOLK | SNV | Missense_Mutation | novel | c.496N>A | p.Glu166Lys | p.E166K | Q9UPQ8 | protein_coding | tolerated(0.12) | probably_damaging(0.987) | TCGA-EO-A3B0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
DOLK | SNV | Missense_Mutation | novel | c.1018N>G | p.Phe340Val | p.F340V | Q9UPQ8 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
DOLK | SNV | Missense_Mutation | novel | c.227N>T | p.Ser76Phe | p.S76F | Q9UPQ8 | protein_coding | deleterious(0.01) | benign(0.351) | TCGA-49-AARN-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
DOLK | SNV | Missense_Mutation | c.1133A>G | p.Tyr378Cys | p.Y378C | Q9UPQ8 | protein_coding | deleterious(0.01) | possibly_damaging(0.843) | TCGA-73-4666-01 | Lung | lung adenocarcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD | |
DOLK | SNV | Missense_Mutation | novel | c.1463N>A | p.Ala488Asp | p.A488D | Q9UPQ8 | protein_coding | tolerated(0.19) | benign(0.354) | TCGA-56-8307-01 | Lung | lung squamous cell carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
DOLK | SNV | Missense_Mutation | novel | c.620A>C | p.Gln207Pro | p.Q207P | Q9UPQ8 | protein_coding | tolerated(0.06) | probably_damaging(0.943) | TCGA-CR-5247-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | paclitaxel | CR |
DOLK | SNV | Missense_Mutation | c.1556N>G | p.Tyr519Cys | p.Y519C | Q9UPQ8 | protein_coding | deleterious(0) | probably_damaging(0.912) | TCGA-BR-4201-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Chemotherapy | cisplatin | SD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |